Nasdaq cprx.

See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Catalyst Pharmaceuticals, Inc. (CPRX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 14.82 +0.39 (+2.70%) At close: 04:00PM EST. 14.85 +0.03 …Sep 30, 2022 11:47AM EDT. Catalyst Pharmaceuticals CPRX announced that the FDA approved its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include ...A couple of Nasdaq stocks saw particularly sharp declines Wednesday morning that stemmed from bad news in their respective businesses. American Airlines Group ( AAL 3.66%) warned that its first ...You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart. NasdaqCM:CPRX Earnings and Revenue History July 30th 2021

CPRX CPRX AFTER HOURS QUOTE CPRX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...

Their CPRX share price targets range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next twelve months. This …

Shareholders of Catalyst Pharmaceuticals ( CPRX -1.13%) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries ( TEVA -1.12%), was planning to ...Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update.The $210.13 million and $294.89 million estimates for the current and next fiscal years indicate changes of +49.2% and +40.3%, respectively. Catalyst reported revenues of $57.24 million in the ...Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high ...

January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...

Catalyst Pharma (NASDAQ:CPRX) is a $1.6bn market cap (at the time of writing) Florida based commercial stage biotech that markets and sells a single product - the neuronal potassium channel ...

CPRX. (NASDAQ:CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%. And in the coming years, that revenue could grow even more.Catalyst Pharmaceuticals Q3 Adjusted Profit, Revenue Rise; Lifts 2023 Guidance. Nov. 09. MT. Earnings Flash (CPRX) CATALYST PHARMACEUTICALS …That number of contracts represents approximately 884,100 underlying shares, working out to a sizeable 52.9% of CPRX's average daily trading volume over the past month, of 1.7 million shares.Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

In the previous quarter, Catalyst Pharmaceuticals (NASDAQ:CPRX) reported ($0.26) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.26). …Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you... Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% Upside

Dec 12, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ... Anyone interested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should probably be aware that the Chief Commercial Officer, Jeffrey Del Carmen, recently divested US$199k worth of shares in the ...

Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, ...Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine).Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. The stock’s 50-day simple moving ...Based in Coral Gables, Florida, Catalyst Pharmaceuticals (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people ...For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...The $210.13 million and $294.89 million estimates for the current and next fiscal years indicate changes of +49.2% and +40.3%, respectively. Catalyst reported revenues of $57.24 million in the ...Catalyst Pharma (NASDAQ:CPRX) is a $1.6bn market cap (at the time of writing) Florida based commercial stage biotech that markets and sells a single product - the neuronal potassium channel ...Nov 10, 2023 · Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.

Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.) Jul-19- ...

See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. CPRX's current price target is $24.75. Learn why top …

Jan 24, 2023 · January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ... Dec 4, 2023 · Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,223 shares of the biopharmaceutical company’s stock after acquiring an additional 1,096 shares during the quarter. Cetera […] Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high ...(NASDAQ:CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera's cash reach into 2025. Together with the expected income ...NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. Tesla, Inc ...10 jam yang lalu ... Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) appoints Michael W. Kalb as Executive Vice President and Chief Financial Officer, ...Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held ...

Dec 12, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ... Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...https://www.catalystpharma.com. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of ...Instagram:https://instagram. what is the best futures trading strategyford motor ex dividend datebest free stock scanners for day tradingprice of gold ingot Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. nyse xpevpsk stock LPL Financial LLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 49.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,878 shares of the biopharmaceutical company’s stock after selling 33,334 shares during the […] itot holdings Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 12.10%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 6. Amount Of Insider Selling (Last 12 Months) $4.07 M. Get CPRX Insider Trade Alerts.Deerfield Management was the largest stakeholder in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, holding 4.9 million shares worth $62.8 million. In total, 18 funds were long ...